Ciproxifan maleate is a highly potent and selective H3-receptor antagonist with IC50 of 9.2 nM. In vitro, Ciproxifan behaved as a competitive antagonist at the H3 autoreceptor controlling [3H]histamine release from synaptosomes and displayed similar Ki values (0.5-1.9 nM) at the H3 receptor controlling the electrically-induced contraction of guinea pig ileum or at the brain H3 receptor labeled with [125I]iodoproxyfan. Ciproxifan displayed at least 3-orders of magnitude lower potency at various aminergic receptors studied in functional or binding tests. In vivo, measurement of compound plasma levels, using a novel radioreceptor assay in mice receiving ciproxifan p.o. or i.v., led to an oral bioavailability ratio of 62%. Oral administration of ciproxifan to mice enhanced by approximately 100% histamine turnover rate and steady state level of tele-methylhistamine with an ED50 of 0.14 mg/kg. Ciproxifan reversed the H3-receptor agonist induced enhancement of water consumption in rats with and ID50 of 0.09 +/- 0.04 mg/kg, i.p. In cats, ciproxifan (0.15-2 mg/kg, p.o.) induced marked signs of neocortical electroencephalogram activation manifested by enhanced fast-rhythms density and an almost total waking state. In rats, ciproxifan enhanced attention as evaluated in the five-choice task performed using a short stimulus duration. Ciproxifan (3mg/kg i.p.) reduced premature responding, a measure of impulsivity.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 50 mg/mL
Ethanol 50 mg/mL
Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease.
Bardgett ME, et al. Neurobiol Learn Mem. 2011 Jan;95(1):64-72. PMID: 21073971.
Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test.
Day M, et al. Biochem Pharmacol. 2007 Apr 15;73(8):1123-34. PMID: 17214974.
Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
Ligneau X, et al. J Pharmacol Exp Ther. 1998 Nov;287(2):658-66. PMID: 9808693.
|Related Histamine Receptor Products|
S 38093 is an inverse agonist at histamine H3 receptors, displays a moderate affinity for rat, mouse and human H3 receptors with Ki of 8.8, 1.44 and 1.2µM, respectively.
Emedastine Difumarate is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity.
Fexofenadine is a nonsedating antihistamine drug which is indicated for treatment of seasonal allergic rhinitis.
|Roxatidine Acetate HCl
Roxatidine Acetate HCl is a specific and competitive histamin H2-receptor antagonist, with IC50 of 3.2 μM, inhibits gastric acid secretion and ulcer formation.
Ranitidine is a histamine H2-receptor antagonist, used to treat stomach or intestinal ulcers.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.